Regentis Biomaterials Ltd. · AMEX:RGNT

Regentis Biomaterials Ltd. financial statements

Regentis Biomaterials Ltd.'s income statement, balance sheet and cash flow, annual and quarterly, each figure dated and linked to the filing it was read from.

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022
Revenue0000
Research and development331.0K1.64M806.0K971.0K
Selling, general and administrative8.29M712.0K1.13M436.0K
Operating income-6.97M932.0K-1.93M-1.41M
Interest expense79.0K10.0K173.0K0
Income before tax13.6M-4.80M4.13M-1.45M
Net income-13.6M4.80M-4.13M-1.45M
Earnings per share, basic-24.161.72-24.09-0.29
Earnings per share, diluted-24.161.72-24.09

Balance sheet

LineFY2025FY2024FY2023FY2022
Cash and equivalents7.38M229.0K345.0K1.24M
Current assets7.62M482.0K360.0K1.72M
Total assets7.62M482.0K360.0K1.72M
Accounts payable266.0K252.0K353.0K206.0K
Current liabilities2.87M6.49M3.14M2.61M
Long-term debt7.41M6.47M
Total liabilities2.87M6.49M46.3M43.8M
Shareholders' equity4.74M-41.1M-45.9M-42.1M
Shares outstanding5.18M162.2K5.18M4.93M

Cash flow

LineFY2025FY2024FY2023FY2022
Cash from operations-1.38M-641.0K-1.22M-1.50M
Capital spending0000
Free cash flow-1.38M-641.0K-1.22M-1.50M
Cash from financing8.52M525.0K325.0K0
Change in cash7.15M-116.0K-895.0K-1.50M